[HTML] frontiersin.org

[HTML][HTML] Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR …

F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
被引用次数：41 相关文章

[引用][C] Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced …

F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - cir.nii.ac.jp
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus
Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated …

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR …

F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - europepmc.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
[HTML] nih.gov

[HTML][HTML] Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced …

F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - ncbi.nlm.nih.gov
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR …

F Chen, N Chen, Y Yu, J Cui - Frontiers in oncology, 2020 - pubmed.ncbi.nlm.nih.gov
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR …

F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - europepmc.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …